NCT03109977View on ClinicalTrials.gov

Imaging With a New Agent That Finds a Cancer Protein Called HER2

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

April 12, 2018

Study Completion Date

April 12, 2018

Conditions
HER2-positive CarcinomaHER2-positive Primary Malignancy
Interventions
DRUG

Zr-DFO-pertuzumab PET/CT

Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy

Trial Locations (1)

10065

Memorial Slaon-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03109977 - Imaging With a New Agent That Finds a Cancer Protein Called HER2 | Biotech Hunter | Biotech Hunter